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Abstract
Pore-forming toxins (PFTs) are by far the most abundant bacterial protein toxins and are important for the virulence of many
important pathogens. As such, cellular responses to PFTs critically modulate host-pathogen interactions. Although many
cellular responses to PFTs have been recorded, little is understood about their relevance to pathological or defensive
outcomes. To shed light on this important question, we have turned to the only genetic system for studying PFT-host
interactions—Caenorhabditis elegans intoxication by Crystal (Cry) protein PFTs. We mutagenized and screened for C. elegans
mutants resistant to a Cry PFT and recovered one mutant. Complementation, sequencing, transgenic rescue, and RNA
interference data demonstrate that this mutant eliminates a gene normally involved in repression of the hypoxia (low
oxygen response) pathway. We find that up-regulation of the C. elegans hypoxia pathway via the inactivation of three
different genes that normally repress the pathway results in animals resistant to Cry PFTs. Conversely, mutation in the
central activator of the hypoxia response, HIF-1, suppresses this resistance and can result in animals defective in PFT
defenses. These results extend to a PFT that attacks mammals since up-regulation of the hypoxia pathway confers resistance
to Vibrio cholerae cytolysin (VCC), whereas down-regulation confers hypersusceptibility. The hypoxia PFT defense pathway
acts cell autonomously to protect the cells directly under attack and is different from other hypoxia pathway stress
responses. Two of the downstream effectors of this pathway include the nuclear receptor nhr-57 and the unfolded protein
response. In addition, the hypoxia pathway itself is induced by PFT, and low oxygen is protective against PFT intoxication.
These results demonstrate that hypoxia and induction of the hypoxia response protect cells against PFTs, and that the
cellular environment can be modulated via the hypoxia pathway to protect against the most prevalent class of weapons
used by pathogenic bacteria.
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Introduction
Pore-forming toxins (PFTs) are by far the most abundant and
amongst the most important bacterial protein virulence factors [1].
These toxins, secreted by many pathogenic bacteria, function by
binding to receptors on host cell plasma membrane, oligomerizing,
inserting, and then forming holes [2]. The importance of PFTs in
promoting bacterial pathogenesis has been demonstrated by
numerous experiments where individual PFTs have been genet-
ically deleted from pathogenic bacteria and the bacteria then
tested for reduced virulence [3]. Examples of PFTs that contribute
significantly to bacterial virulence include a-toxin by Clostridium
septicum, streptolysins by Group A and B Streptococci, a-toxin by
Staphylococcus aureus, Vibrio cholerae cytolysin (VCC), a-hemolysin
from uropathogenic E. coli, cytolysin from Enterococcus faecalis, and
crystal (Cry) proteins from Bacillus thuringiensis (Bt).
Although they are expressed by many bacterial pathogens and
are broadly important as potentiators of infection, the effects of
these toxins on host cells have been vastly understudied. There are
several reasons for this lack of attention. First, their mechanism of
action is deceptively simple. Second, most of the attention has
been given to understanding how PFTs can change conformation
from secreted, soluble proteins to insoluble proteins embedded in
the plasma membrane. Third, because breaching of the plasma
membrane is a major insult to a cell, a multitude of cellular
responses to PFTs have been reported, including Ca
2+ influx, K
+
efflux, increased endocytosis/exocytosis, vacuolization, necrosis,
and apoptosis [3,4,5,6]. Because the responses are so large and
extensive, it has been daunting to determine whether these
responses contribute to defense, intoxication, both, or neither.
Fourth, most of the studies carried out to date involved cells in
isolated culture, which does not always accurately recreate the
response of cells to toxins in the context of intact tissue.
To address many of these limitations, an excellent genetic
system for studying PFT responses in an intact animal has recently
emerged: the Bacillus thuringiensis (Bt) Crystal (Cry) PFT –
Caenorhabditis elegans toxin-host interaction system [7]. C. elegans
has become an important genetically tractable organism for
studying immune responses to bacterial pathogens [8]. Bt is
thought to be a natural pathogen of C. elegans [9,10,11] and is
famous for the production of three-domain PFTs that are widely
used in insect biocontrol [12]. The interaction of Cry proteins with
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identified, p38 mitogen-activated protein kinase (MAPK) pathway
[13]. Loss of the p38 MAPK pathway was shown to result in loss of
protection against Cry PFTs in C. elegans and was subsequently
shown to result in loss of protection against PFTs in mammalian
cells as well [13,14]. This same system was used to discover that
the unfolded protein response (UPR) is also required for PFT
defenses as a downstream target of the p38 MAPK pathway [15].
Both the p38 MAPK pathway and the UPR were demonstrated to
be activated by PFTs in C. elegans and mammals [15,16]. Apart
from these studies, only one other study to date has demonstrated
a specific molecular pathway as involved in PFT responses [17].
Since, when studying intracellular PFT response pathways in
the past, we have screened for C. elegans mutants hypersensitive to
PFTs [13,15], we reasoned that we could learn something different
by screening for the opposite phenotype– C. elegans mutants
resistant to PFTs. The reason for this assumption is that no
intracellular pathway mutants were known that can make cells
resistant to PFTs in general. Here we report on the results of a
PFT resistance screen and find, unexpectedly, that resistance can
be achieved by mutations that up-regulate the C. elegans low
oxygen (hypoxia) response. Elimination of HIF-1 (hypoxia
inducible factor 1), the main effector of the hypoxia pathway,
abrogates this resistance and can lead to PFT hypersensitivity.
This protection applies to multiple different PFTs and is clearly
distinguished from the role of the HIF-1 pathway in other stress
responses and aging. Furthermore, the hypoxia pathway is
activated in response to PFTs, and low oxygen is itself protective
against PFT attack. Our results indicate that the hypoxia/low
oxygen response is likely to be of general importance for cellular
responses to small-pore PFTs.
Results
Isolation and identification of a mutant resistant to Bt
Cry21A toxin
To identify pathways important for cellular responses to PFTs,
we screened for mutants resistant to the PFT Cry protein, Cry21A.
Cry21A is a three-domain Cry protein that targets nematodes and
is in the same family as Cry5B [11]. Like Cry5B [18], secondary
structure programs predict Cry21A contains all the a helical
segments that are involved in pore-formation in three-domain Cry
proteins [19]. All three-domain Cry proteins, like Cry5B and
Cry21A, are believed to act as PFTs, and pore-forming activity has
been demonstrated for all Cry proteins so studied to date [12]. In
the past, we have screened for mutants resistant to Cry5B, which
has given rise to detailed understanding of the Cry5B receptor
[20,21,22] but not to information on intracellular responses to Cry
PFTs. Our rationale for screening for Cry21A PFT resistant
animals was that it could elucidate new information about how
cells respond to PFTs since Cry5B resistant mutants are only
weakly resistant to Cry21A.
To perform this screen, C. elegans hermaphrodites were
mutagenized with EMS and allowed to self-fertilize for two
generations. Sixty eight thousand F2 mutagenized hermaphrodites
were fed an intoxicating dose Cry21A PFT and then screened for
those that resisted intoxication. One mutant line, allele ye49, was
identified that bred true and is resistant to Cry21A PFT produced
either from Bt or E. coli (Figures 1A and 1B).
To identify the gene mutated in ye49, we performed standard
three-factor and single-nucleotide mapping experiments, which
narrowed the search to a region on chromosome V, between
markers snp_F15H10 and snp_T21C9, that includes 43
genes. Mutation in one of the genes in this region, egl-9, had
been previously identified as resistant to cyanide produced by
Pseudomonas aeruginosa PA01 [23]. We therefore performed com-
plementation testing between ye49 and the egl-9 null allele
egl-9(sa307) and found that ye49/egl-9(sa307) animals are resistant
to Cry21A PFT, indicating ye49 fails to complement egl-9(sa307)
and most probably mutates the same gene (Figure 1C). Further-
more, injection of an extrachromosomal array bearing the egl-9
promoter and coding region restored wild-type Cry21A suscepti-
bility to ye49 animals (Figure 1D). In addition, sequencing of egl-9
cDNA isolated from the ye49 mutant identified a point mutation
(W508-to-stop) that upon translation is predicted to truncate the
protein in the prolyl hydroxylase domain, thereby eliminating
protein hydroxylase function (Figure 1E). These results demon-
strate that Cry21A PFT resistance phenotype associated with ye49
is due to loss of egl-9 function mutation. As predicted from this
conclusion, feeding of double-stranded RNA to cause RNA
interference (RNAi) results in animals resistant to Cry21A
(Figure 1F).
The hypoxia pathway is required for protection against
Cry PFTs
The EGL-9 protein is a prolyl hydroxylase and functions in the
C. elegans low oxygen response (hypoxia) pathway (Figure 2A; [24]).
The ability of cells to respond to hypoxia is mediated by a
transcription factor called HIF-1a. Under normal oxygen
(normoxia) conditions, HIF-1a (called HIF-1 in C. elegans)i s
hydroxylated by a prolyl hydroxylase (EGL-9 in C. elegans or PHD
in mammals) that then increases HIF-1’s affinity for von Hippel-
Lindau tumor suppressor protein (called VHL-1 in C. elegans), part
of an E3 ubiquitin ligase complex. Association of HIF-1 with
VHL-1 eventually leads to HIF proteasomal degradation. When
EGL-9 is disabled by mutation, HIF-1 is stabilized at constitutively
high levels even under normoxic (normal oxygen) conditions [25].
Since loss of EGL-9 function confers resistance to Cry21A PFT,
we hypothesized that other elements of the hypoxia pathway
might be important as well. We therefore performed quantitative
dose-dependent mortality assays using null or putative null alleles
of all the above elements of the hypoxia pathway. L4 staged
Author Summary
Bacteria make many different protein toxins to attack our
cells and immune system in order to infect. Amongst them,
pore-forming toxins (PFTs), which punch holes in the
protective plasma membrane that surrounds cells, are by
far the most abundant and constitute important virulence
factors. Since the integrity of the plasma membrane is
fundamental to maintaining the normal intracellular envi-
ronment, the breaching of the plasma membrane by
PFTs results in many and dramatic intracellular responses.
However, we know little about the relevance of these
responses to cell survival or cell intoxication. Here, using the
only genetic system for studying pore-forming toxin effects
in a whole animal, we show that the same response that
protects cells against low oxygen stress unexpectedly also
protects cells against pore-forming toxins. Mutations in the
animalthathyper-activatethelowoxygenresponseactually
make animals resistant to pore-forming toxin attack,
whereas mutations that inactivate the low oxygen response
make animals more susceptible. Furthermore, a low oxygen
environment itself is protective against pore-forming toxins.
These data show a new and powerful connection between
low oxygen responses and defense against the single most
common mode of bacterial attack.
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numerous doses of Cry21A PFT or Cry5B PFT and scored for
viability after a few days (Figures 2B and 2C).
As predicted from the above studies, we find that animals
lacking EGL-9 are quantitatively resistant to Cry PFTs. At doses
from 1–16 mg/mL Cry21A and 10–80 mg/mL Cry5B PFTs, egl-
9(sa307) and egl-9(ye49) animals are resistant to PFT-induced
mortality relative to wild-type animals, with resistance strongest
at higher PFT doses (Figures 2B and 2C; Table 1). For example,
76–106more egl-9 mutant animals are alive at 8 mg/mL Cry21A
or 40 mg/mL Cry5B PFT than wild-type animals at the same
doses (P,0.001; Table 1; note, direct dose comparison between
Cry21A and Cry5B toxicity is not possible since Cry21A assays are
performed with Bt spore-crystal lysates and Cry5B assays with
purified protein). Based on LC50 values (concentration at which
50% of the animals are dead), loss of EGL-9 results in 3–5 fold
resistance over wild-type animals to Cry21A or Cry5B PFTs
(Table 1). Note, since all our mortality assays are carried out in
liquid medium, resistance to the PFT cannot be attributed to
improved avoidance behaviors. Cry21A PFT resistance was also
confirmed using a quantitative brood size assay (Figure S1).
We also found that vhl-1(ok161) mutant animals are resistant
over a similarly wide range of Cry21A and Cry5B PFT doses
(Figures 2B and 2C; Table 1). For example, 6.26and 7.46more
vhl-1 mutant animals are alive at 8 mg/mL Cry21A and 40 mg/mL
Cry5B, respectively, than wild-type animals. Based on LC50
values, vhl-1 mutant animals are 46resistant to Cry5B PFT. We
also tested rhy-1(ok161) mutant animals on Cry21A PFT. RHY-1
Figure 1. Cry21A PFT-resistant ye49 mutates egl-9. Hermaphrodites from N2 wild-type and ye49 animals after feeding on (A) Bt spore crystal
lysates for 72 h without or with Cry21A crystal protein or (B) E. coli expressing no toxin or Cry21A. ye49 animals on Cry21A from either Bt or E. coli are
clearly healthier than wild-type animals on Cry21A, as they are bigger, darker, and more motile. (C) Complementation tests. Images of representative
animals 48 h after feeding on E. coli expressing Cry21A. Top row: controls showing relative sickness of wild-type N2 animals on Cry21A compared to
ye49 and egl-9(sa307) animals on Cry21A. Bottom rows: heterozygous over wild type controls showing egl-9(sa307)/+ and ye49/+ animals are sensitive
to Cry21A; ye49/egl-9(sa307) animals showing resistance to Cry21A. These animals are also all heterozygous for dpy-17(e164), used as a marker to
distinguish self from cross progeny. (D) Rescue experiments. Images of representative animals 48 h after feeding on E. coli expressing Cry21A. Top:
controls showing relative health of wild-type N2 and ye49 animals on Cry21A. Bottom: animals of the genotype ye49 transformed with genomic wild-
type egl-9 DNA showing that expression of egl-9 in ye49 animals rescues Cry21A resistance. (E) Location of amber mutation in egl-9 gene associated
with ye49 (*) as well as locations of the egl-9(sa307) deletion (bar) and egl-9(RNAi) clone (dotted line) from the Ahringer library [59]. Boxes represent
exons. (F) RNAi of egl-9 results in animals resistant to Cry21A. L4440 is empty vector RNAi control (no gene knock down). RNAi animals were fed
Cry21A for 24 hours. Scale bar is 0.5 mm in this and all figures unless otherwise specified.
doi:10.1371/journal.ppat.1000689.g001
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by inhibiting expression of some HIF-1 target genes via a VHL-1
independent pathway [26]. Animals lacking RHY-1 are also
resistant to Cry21A (Table 1; Figure S2). Based on LC50 values,
animals lacking RHY-1 are 5.76 resistant to Cry21A PFT
(Table 1). These data demonstrate that loss of function mutations
in genes that normally antagonize HIF-1 function all result in
resistance to Cry protein PFTs. In other words, stimulation of
HIF-1 function via removal of HIF-1 inhibitory factors results in
PFT resistance.
To confirm that the resistance associated with egl-9 mutants was
going through HIF-1, we looked at the dose-dependent response of
hif-1(ia04) and egl-9(sa307) hif-1(ia04) double mutant animals to
Cry21A and Cry5B PFTs. When fed Cry21A, hif-1(ia04) animals
have a response that is indistinguishable from wild-type animals
(Figure 2B; Table 1). egl-9(sa307) hif-1(ia04) double mutant
animals have a statistically identical response to Cry21A as wild-
type animals at all doses except at 8 mg/mL (Table 1). Further-
more the LC50 values of hif-1(ia04) and egl-9(sa307) hif-1(ia04)
animals on Cry21A PFT are statistically identical (P.0.05) but
both statistically different than that of egl-9(sa307) (P,0.01;
Table 1). These results have been qualitatively confirmed using
RNAi—whereas wild-type animals subject to egl-9 RNAi are
resistant to Cry21A, hif-1(ia04) mutant animals subject to egl-9
RNAi are not (Figure S3). Similarly, whereas egl-9(sa307) mutants
are resistant to Cry21A, this resistance is suppressed by RNAi of
hif-1. Thus, HIF-1 is required for Cry21A resistance mediated by
loss of EGL-9.
The results with Cry5B PFT are similar to those of Cry21A
(Figure 2C; Table 1) in that HIF-1 is required for Cry5B resistance
mediated by loss of EGL-9 (i.e., loss of HIF-1 suppresses Cry5B
PFT resistance associated with loss of EGL-9). There is, however,
one striking difference between the hif-1 results with Cry21A and
Cry5B. Both hif-1(ia04) and egl-9(sa307) hif-1(ia04) animals are
hypersensitive to Cry5B PFT relative to wild-type animals. That is,
animals lacking HIF-1 are more readily killed by Cry5B PFT than
wild-type animals, especially at doses ,5–10 mg/mL (P,0.05;
Figure 2C; Table 1). Thus, hif-1 is required for intrinsic cellular
defenses (INCED) [15] against Cry5B PFT. With regards to the
different results with Cry5B and Cry21A, we speculate that
perhaps Cry5B PFT intoxicates more potently than Cry21A and
that, whereas increased HIF-1 activity is protective against all
PFTs, loss of HIF-1 activity is more acutely felt when the stronger
PFT is present. In the case of Cry21A, other INCED pathways are
sufficient for full protection even in the absence of HIF-1.
The hypoxia pathway is required for defense against
V. cholerae cytolysin
Cry proteins are small-pore PFTs. To test whether or not the
hypoxia pathway was more generally required for INCED against
PFTs, we fed C. elegans two V. cholerae strains that differ primarily in
their ability to produce another small-pore PFT, VCC. VCC is a
virulence factor of V. cholerae and mutants lacking VCC are
attenuated for pathogenesis in vivo, especially for strains lacking
cholera toxin [27,28]. The strains we use are CVD109(VCC+) and
CVD110(VCC2) that are nearly isogenic (except for the presence
of cholera toxin B subunit in CVD110, which should not matter
since C. elegans lacks sialic acid that the B subunit binds to as part of
its GM1 receptor [29]). Although both strains are pathogenic
when fed to C. elegans, CVD109(VCC+) is more virulent than
CVD110(VCC2), demonstrating that VCC is a virulence factor
for C. elegans (Figure 3A).
Our results with hypoxia pathway mutants on CVD109(VCC+)
and CVD110(VCC2) are striking and parallel those with Cry
PFTs. When feeding on CVD109(VCC+), egl-9(sa307) animals are
resistant relative to wild-type animals (Figure 3A; Table 2; median
survival 4 vs. 3 days respectively; P,0.001). This resistance is
dependent upon the presence of VCC since when feeding on
CVD110(VCC2), egl-9(sa307) animals are not resistant (Figure 3A;
Table 2). Similarly, hif-1(ia04) and egl-9(sa307) hif-1(ia04) animals
are, as with Cry5B PFT, hypersensitive relative to wild-type
animals on CVD109(VCC+) (median survival of 2, 1, and 3 days
respectively; P,0.0001; Figure 3B; Table 2). This hypersensitivity
is dependent upon the presence of VCC since these mutants are
Figure 2. Quantitative response of egl-9 and HIF-1 pathway
mutants to Cry PFTs. (A) Schematic illustrating O2-dependent
regulation of HIF-1 activity. The O2-dependent prolyl hydroxylation of
HIF-1 by EGL-9/PHD increases its affinity to VHL-1, leading to
ubiquitylation and destruction. (B, C) Dose-dependent mortality assays
were performed using (B) Cry21A spore crystal lysates or (C) purified
Cry5B to quantitatively compare sensitivities of wild-type N2, egl-9
mutants, and HIF-1 pathway mutants to PFTs. Each data point shows
the mean and standard errors of the mean of results from three
independent experiments (three wells per experiment; on average, 180
animals per data point). Statistical differences between mutant strains
and N2 are given for each concentration using P values represented by
asterisks as follows: * P,0.05; ** P,0.01; *** P,0.001. Percent alive at
specific doses and LC50 values are reported in Table 1.
doi:10.1371/journal.ppat.1000689.g002
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Table 2). It is interesting to note that egl-9(sa307) mutant animals
are hypersensitive compared to wild-type animals to
CVD110(VCC2) strain (median survival of 4 and 6 days
respectively; P,0.0001; Figure 3A; Table 2). We speculate that
while activation of the hypoxia pathway (in an egl-9 mutant or
otherwise) protects the animals against VCC and PFTs (hence egl-9
mutants are resistant to the VCC+ strain), activation of the
hypoxia pathway may make the animals more susceptible to other
V. cholerae virulence factors. The relative contribution to these
responses (protection versus susceptibility) is dependent upon
which virulence factors are present and their relative contribution
to virulence. In the VCC+ strain, the PFT has important function.
Hence, the protective role of pathway activation can be discerned.
In the VCC2 strain, the PFT defense is no longer needed. Hence,
the susceptible role can be discerned. It is this give-and-take
interaction between the host and virulence factors that could
partly explain why constitutive mutation in egl-9 is not selected in
the wild. In any event, taken together, our Cry PFT and VCC
data demonstrate that stabilization of HIF-1 results in resistance to
VCC PFT whereas loss of HIF-1 results in hypersensitivity to
VCC PFT.
Table 1. Data and analyses for Cry21A and Cry5B dose-dependent mortality assays.
Cry21A concentration (mg/mL)
Strains
1
%alive
2
%alive
4
%alive
8
%alive
16
%alive
N2 76.50 55.96 28.59 7.21 5.96
egl-9(ye49) 100** 97.49*** 85.81*** 56.65*** 41.14***
egl-9(sa307) 97.86** 95.76*** 89.18*** 71.52*** 57.10***
hif-1(ia04) 91.13 52.90 32.03 10.60 8.51
egl-9(sa307)hif-1(ia04) 89.99 70.31 41.22 23.26* 19.54
vhl-1(ok161) 99.38** 82.86*** 72.10*** 44.96*** 15.24
N2 76.19 44.32 18.63 3.60 0.69
rhy-1(ok1402) 95.47* 85.82*** 77.01*** 63.35*** 40.51***
Cry5B concentration (mg/mL)
Strains
5
%alive
10
%alive
20
%alive
40
%alive
80
%alive
N2 72.22 45 15.32 4.64 0.65
egl-9(ye49) 79.73 70.04*** 58.64*** 33.88*** 15.78*
egl-9(sa307) 79.93 71.74*** 59.22*** 39.85*** 20.23***
hif-1(ia04) 38.29*** 14.85*** 1.88* 1.11 1.05
egl-9(sa307)hif-1(ia04) 45.87*** 16.32*** 4.26 1.73 0.69
vhl-1(ok161) 91.36*** 87.31*** 63.16*** 34.70*** 19.55***
Cry21A assay LC50 (mg/mL) Standard deviation Relative resistance (LC50 wild type/LC550 mutant)
N2 4.8 2.1
egl-9(ye49) 17.1** 3.5 3.5
egl-9(sa307) 25.0*** 2.9 5.2
hif-1(ia04) 5.5 1.9 1.1
egl-9(sa307)hif-1(ia04) 8.7
a,b 2.8 1.8
vhl-1(ok161) 11.6 3.3 2.4
N2 3.1 0.9
rhy-1(ok1402) 17.4* 3.9 5.7
Cry5B assay
N2 7.1 1.3
egl-9(ye49) 22.8 7.0 3.2
egl-9(sa307) 27.9** 15.8 3.9
hif-1(ia04) 3.4 1.4 0.5
egl-9(sa307)hif-1(ia04) 3.7
c,b 1.6 0.5
vhl-1(ok161) 28.7** 8.0 4.0
Statistical differences between mutant strains and N2 wild-type are given for each concentration and LC50 using P values represented by asterisks as follow: * P,0.05, **
P,0.01, *** P,0.001.
aP value,0.001 for comparison with egl-9(sa307).
bP value.0.05 for comparison with hif-1(ia04).
cP value,0.01 for comparison with egl-9(sa307).
doi:10.1371/journal.ppat.1000689.t001
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can be differentiated from other stressors
Because loss of EGL-9 results in resistance to PFTs (here) and
cyanide [23,30], we hypothesized that egl-9 mutant animals might
show resistance to other stressors as well. We found that, relative to
wild-type animals, animals lacking EGL-9 are resistant to killing by
1) the pathogen Pseudomonas aeruginosa PA14; 2) heat stress; and 3)
oxidative stress (Figure 4A, Table 2; Figures 4B and 4C). Since
correlationbetweenstressresponse andlifespanhadpreviouslybeen
reported, such as in the daf-2 mutant [31,32], we tested whether loss
of EGL-9 had an effect on longevity. Indeed, egl-9(ye49) and
egl-9(sa307) mutant animals live longer than N2 wild-type when
feeding on the standard E. coli strain (Figure 4D, Table 2).
To study the relationship between the hypoxia response
pathway and resistance to stresses in more detail, we asked if the
resistance to these different stresses via loss of EGL-9 was, as for
resistance to PFTs, mediated through HIF-1. Unexpectedly, we
found that hif-1(ia04) loss-of-function mutant animals as well as egl-
9(sa307) hif-1(ia04) mutant animals are resistant to P. aeruginosa
PA14 infection, heat stress, and oxidative stress (Figure 4E,
Table 2; Figures 4F and 4G). Both mutant strains are also long
lived (Figure 4H; Table 2). Thus, in the case of these stresses, but
unlike that of PFT response, loss of either EGL-9, HIF-1, or both
results in stress resistance. We speculate that, in the case of these
other stresses, hydroxylation of HIF-1 by EGL-9 may result in its
activation prior to degradation. Similar results have been
previously reported in that mutation of either hif-1 or egl-9 results
in C. elegans resistant to pathogenic E. coli [33]. With regards to
lifespan, published studies are contradictory but there is at least
one published report with egl-9 mutants long lived and two with
hif-1 long-lived [34,35,36]. In any event, our results demonstrate
that role of the hypoxia pathway in PFT INCED is separable from
that of other stress responses.
The hypoxia pathway functions cell-autonomously in PFT
responses
Bt Cry PFTs attack intestinal cells [21,22,37]. It is possible that
the hypoxia defense pathway functions within the cells targeted by
the PFTs or that the hypoxia pathway is functioning cell non-
autonomously. To address this question, we expressed egl-9 under
the control of various promoters including the intestinal specific
cpr-1 promoter [21,22,38] and the unc-31 promoter, which is
expressed in all neurons and in secretory cells of the somatic gonad
[39]. We find that expression of wild-type EGL-9 under the cpr-1
promoter in the intestinal cells of egl-9(sa307) animals (Figure 5),
but not under the unc-31 promoter in the neuronal or secretory
cells (not shown), is sufficient to rescue the egl-9(sa307) Cry21A
resistance phenotype. Control animals in which green-fluorescent
protein (GFP) was expressed from the cpr-1 promoter did not result
in rescue. Quantitative mortality assays using two independent
lines of cpr-1::egl-9-transformed egl-9(sa307) mutant animals
confirm that intestinal-specific expression of EGL-9 rescues
Cry21A PFT resistance to a level statistically indistinguishable
from N2 wild-type (not shown). These data are consistent with the
hypoxia pathway acting to directly counteract the effects of PFTs
and not, for example, providing protection via altered behavior.
The UPR and the nuclear receptor nhr-57 are
downstream effectors of the hypoxia PFT INCED
To address how the hypoxia pathway might function in
protection against PFTs, we sought in two ways to find functional
downstream effectors of the pathway. First, we compared known
functional targets of the hypoxia pathway in C. elegans and asked if
any of these are involved in PFT defenses. One pathway
immediately surfaced, the unfolded protein response or UPR
[40]. It has been recently reported that the hypoxia pathway
genetically functions upstream of the XBP-1 arm of the UPR with
Figure 3. egl-9 mutation confers resistance to V. cholerae VCC. (A) The survival of wild-type N2 and egl-9(sa307) mutant animals on V. cholerae
CVD109(VCC+) and CVD110(VCC2) are shown. (B) The survival of wild-type N2, hif-1(ia04), and egl-9(sa307) hif-1(ia04) mutant animals on V. cholerae
CVD109(VCC+) and CVD110(VCC2) are shown. Quantitative data and statistical analyses for the representative experiment shown here are included
in Table 2. Data for two other independent repetitions of the experiment are shown in Table S1.
doi:10.1371/journal.ppat.1000689.g003
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previously shown that the XBP-1 is required for PFT INCED
since loss of XBP-1 leads to animals that are hypersensitive to
Cry5B PFT [15]. These data suggest that the XBP-1 arm of the
UPR is one downstream target of the hypoxia PFT INCED.
To test this suggestion, we examined whether or not the hypoxia
pathway regulates activation of the XBP-1 UPR pathway.
Activation of the XBP-1 UPR pathway can readily be discerned
by examining xbp-1 mRNA, which is spliced upon activation of the
pathway [41]. We indeed find that activation of the hypoxia
pathway results in activation of the UPR as seen by a 1.4 fold
increase in spliced xbp-1 levels in egl-9 mutant animals (P,0.001;
see Materials and Methods). Thus, one functional downstream
effector of the hypoxia pathway for PFT defenses is the XBP-1
UPR.
We conversely asked if any of the genes known to be involved in
PFT INCED are known to be important for the hypoxia pathway.
From over 100 PFT INCED genes we have identified in our lab,
we found one and only one currently known to be regulated by the
hypoxia pathway, nhr-57. nhr-57 was initially identified as part of
the hypoxia pathway by the fact that its expression is positively
regulated by hif-1 and negatively regulated by egl-9 and vhl-1
[42,43]. In fact, nhr-57 transcriptional activation is considered the
most reliable marker for activated HIF-1 function in C. elegans [26].
We confirmed using quantitative PCR that in egl-9 mutant
animals, nhr-57 transcripts are induced 15 fold and that this
increase is completely dependent upon HIF-1 (data not shown).
However, to date no functional role of nhr-57 for any HIF-1-
regulated pathway has been shown.
We find that knock down of nhr-57 results in animals slightly but
statistically hypersensitive to Cry5B PFT (e.g., 21% reduction in
viability for nhr-57 RNAi at 20 mg/mL Cry5B PFT versus vector-
only RNAi control, P=0.02; n=90; see Materials and Methods)
and therefore defective in PFT INCED. More impressively, we
find that knock down of nhr-57 completely suppresses the
resistance to Cry21A PFT associated with loss of EGL-9
(Figure 6). Taken together, these results indicate that the nuclear
receptor nhr-57 is a second functional downstream effector of the
hypoxia PFT defense pathway.
The hypoxia pathway is induced by PFT and hypoxia is
protective against PFT
Although the above data demonstrate the hypoxia pathway is
important for PFT INCED, they do not directly address whether
the defense against PFTs is related to a low oxygen response or to
some other function of the HIF-1 pathway. We therefore
examined whether the hypoxia pathway itself is activated by
PFTs using nhr-57 expression, the canonical marker for HIF-1
pathway activation by low oxygen in C. elegans (see above). We find
that 4 and 8 hours of treatment with PFT significantly induces
nhr-57 expression 5.3 and 3.6 fold respectively (Figure 7A). Shorter
treatments with PFT do not. Thus, PFT induces the hypoxia
pathway.
If a low oxygen response is involved in responding to PFTs, then
one might predict that exposure to low oxygen might confer
protection against PFT attack since the low oxygen environment
might strongly and rapidly induce the correct protective response.
We therefore exposed C. elegans hermaphrodites to low (2%)
oxygen levels minus or plus the presence of E. coli-expressing
Cry5B PFT. We find that low oxygen is indeed protective against
PFT intoxication in that animals exposed to PFT in a low oxygen
environment for 24 hours are significantly healthier than animals
exposed to PFT in normoxia (Figure 7B). Similar results were
obtained for animals exposed to a low oxygen environment for
three days (Figure S4). In contrast and as expected, hif-1(ia04)
mutant animals exposed to Cry5B PFT do not get any protection
when placed in a hypoxic environment (Figure 7B), confirming
that the protective effect of hypoxia against PFT is due to
activation of the HIF-1 pathway.
Discussion
Our results demonstrate that the hypoxia pathway protects
C. elegans against PFTs, whether Bt Cry protein PFTs or a PFT
used by a mammalian pathogen, V. cholerae VCC. We find that
activation of HIF-1 pathway by removal of any of EGL-9/PHD,
VHL-1, or RHY-1, makes C. elegans more resistant to PFTs than
they normally are. This resistance is completely abrogated upon
loss of HIF-1, which can additionally result in animals hypersen-
sitive in PFTs. Resistance to PFTs functions in the cells directly
targeted by PFTs and is not associated with other hypoxia-
mediated stress resistance phenotypes. Furthermore, exposure to
PFT induces transcriptional activation of the HIF-1 low oxygen
pathway, and exposure of animals to low oxygen protects animals
against PFT intoxication, through a HIF-1-dependent mechanism.
A schematic summarizing our findings here is in Figure 7C.
Consistent with our finding that activation of the HIF-1 pathway is
protective against PFTs, it has been shown that expression of the
HIF-1a protein is increased in human airway cells by S. aureus
supernatants, of which a-toxin is a major constituent [44].
Table 2. Data and analyses of VCC, PA14, and lifespan assays.
V. cholerae assays
median survival
(days)
p value for comparison
with the N2 survival curves
N2/CVD109(VCC+)3
egl-9(sa307)/CVD109(VCC+)4 ,0.0001
hif-1(ia04)/CVD109(VCC+)2 ,0.0001
egl-9(sa307)hif-1(ia04)/
CVD109(VCC+)
1 ,0.0001
N2/CVD110(VCC2)6
egl-9(sa307)/CVD110(VCC2)4 ,0.0001
hif-1(ia04)/CVD110(VCC2)6 .0.05
egl-9(sa307)hif-1(ia04)/
CVD110(VCC2)
6 .0.05
P. aeruginosa PA14
assays
median survival
(hours)
p value for comparison
with the N2 survival curves
N2 50
egl-9(ye49) 70 ,0.0001
egl-9(sa307) 60 ,0.001
N2 40
hif-1(ia04) 48 ,0.0001
egl-9(sa307)hif-1(ia04) 52 ,0.0001
Lifespan analysis
median survival
(days)
p value for comparison
with the N2 survival curves
N2 15
egl-9(ye49) 20 ,0.01
egl-9(sa307) 17 ,0.05
N2 15
hif-1(ia04) 18 ,0.001
egl-9(sa307)hif-1(ia04) 20 ,0.001
doi:10.1371/journal.ppat.1000689.t002
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is associated with low oxygen in cells, and that the hypoxia
pathway is therefore needed to protect the cells against this
condition. Alternatively, although less parsimoniously, it is possible
that both hypoxia and PFTs trigger the same set of HIF-1
downstream mediators that are protective against both assaults but
that are not otherwise linked by the presence of low oxygen. Two
downstream effectors of the hypoxia PFT INCED pathway are the
UPR and nhr-57. The fact that nhr-57 is involved in hypoxia PFT
INCED suggests that multiple transcriptional responses are key to
mounting an effective defense against PFTs. The link between the
XBP-1 UPR, hypoxia, and PFTs is intriguing. It has already been
shown in mammalian cells that hypoxia induces activation of the
XBP-1 UPR as detected by an up-regulation in xbp-1 mRNA
splicing by low oxygen [45]. Furthermore, it has been shown that
XBP-1 protects cells against hypoxia-induced apoptosis [45].
Therefore, we speculate that one role of the hypoxia pathway in
PFT INCED is to induce an XBP-1-linked protective response
against PFT/low oxygen-mediated apoptosis. Given that the p38
MAPK pathway is also linked to PFT defenses and the UPR, it
will be interesting to explore further links between hypoxia, the
UPR, p38 and apoptotic pathways in response to PFTs.
Although this report is not the first of hypoxia pathway
involvement in immunity, it is the first showing a link between
hypoxia and protection of cells that are being directly attacked by
a virulence factor. Control of the metabolic shift to glycolysis by
HIF-1a has been shown to play an important role in myeloid cell-
mediated inflammatory response [46]. Furthermore, it has been
Figure 4. egl-9 and hif-1 mutant phenotypes on other stressors and on aging. (A) The survival of wild-type N2 and egl-9 mutant animals on
P. aeruginosa PA14 are shown for one representative assay (n.50). (B) egl-9 mutant and N2 animals were scored for viability after 12 h exposure to
35uC. Data are averaged from three independent experiments with n.30 for each. Error bars represent standard error of the mean, * represents P
values,0.05 and ** P values,0.01. (C) Comparison of egl-9 mutant animals to wild-type animals on hydrogen peroxide. Representative worms are
shown for each strain 6 h after continual treatment. Wild-type N2 animals are still alive but paralyzed, whereas egl-9 mutant animals are active and
healthy, indicative of resistance. (D) Lifespan of N2 and egl-9 mutants feeding on E. coli OP50 (n.30 animals per strain). One of three representative
experiments shown. (E–G) hif-1(ia04) and egl-9(sa307) hif-1(ia04) mutant animals challenged with (E) P. aeruginosa PA14 (one of three representative
experiments shown), (F) heat shock at 35uC for 14 h, and (G) oxidative stress (hydrogen peroxide; both mutant strains are still active, unlike N2
animals). (H) Lifespan of hif-1(ia04) and egl-9(sa307) hif-1(ia04) mutant animals feeding on E. coli OP50. Quantitative data and statistical analyses for
the experiments shown here are included in Table 2. Independent repeats for the PA14 and lifespan assays are shown in Table S1.
doi:10.1371/journal.ppat.1000689.g004
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stimulate HIF-1a transcriptional activity in macrophages, regu-
lating the expression of immune effectors molecules, including
antimicrobial peptides, nitric oxide and tumor necrosis factor-a
[47]. Our results point to a new and different role of the hypoxia
pathway, namely in providing autonomous protection of epithelial
cells against PFTs.
To our knowledge, these results are the first to demonstrate that
an intracellular pathway can be altered to promote general
resistance to PFTs. Although a few receptor mutants that confer
resistance to PFTs have been previously identified, these do not
confer general resistance. A logical extension of our findings is that
significant therapeutic benefit against a wide range of bacterial
pathogens such as S. aureus, Streptococci, Clostrida, V. cholerae (all of
which use PFTs as virulence factors) could be achieved by up-
regulation of HIF-1 and/or by hypoxia. The identification of the
hypoxia pathway as an important PFT INCED pathway thus
unexpectedly provides a novel and potentially powerful means of
protecting against the single most common mode by which
bacterial pathogens attack us.
Materials and Methods
C. elegans maintenance and microscopy
Strains were maintained at 20uC under standard conditions [48].
The wild-type strain for this study is N2 Bristol [48]. The strains egl-
9(sa307), hif-1(ia04), egl-9(sa307) hif-1(ia04), vhl-1(ok161), rhy-
1(ok1402), the Hawaiian strain CB4856 and HT1593 [unc-119
(ed3)] were obtained from the Caenorhabditis Genetic Center (CGC).
All strains were either previously outcrossed or outcrossed here at
least six times (e.g., egl-9(ye49), rhy-1(ok1402)). egl-9(sa307) is a null
allele of egl-9 that carries an internal 243-bp deletion removing part
of exons 5 and 6 [23]. hif-1(ia04) allele removes exons 2, 3 and 4 of
hif-1, including the DNA binding domain, and is believed to be a
null allele [49]. The vhl-1(ok161) allele removes exons 1 and 2 of
vhl-1 and is believed to be a null allele [25]. The rhy-1(ok1402) allele
deletes exons 2, 3 and 4 of rhy-1 and is also believed to be null
[26]. Images were acquired using an Olympus SZ60 dissecting
microscope and a Canon PowerShot A620 digital camera.
Production of a recombinant Cry21A Bt strain and
spore-crystal lysates (SCLs)
For production in Bt, the cry21A gene was cloned under 700 bp
of the cry6A promoter region and subcloned into the Bt/E. coli
shuttle vector pHT3101. The plasmid was transformed into a
nontoxic host Bt strain (4D22). Cry21A SCLs were prepared using
standard procedures [50] and the concentration was measured
relative to BSA standards on protein gels.
Genetic screen for Cry21A resistance mutants
Mutagenesis and selection of Cry21A resistance mutants was
carried out as described for Cry5B [20] except Cry21A SCLs were
used to a final concentration of 0.25 mg/mL Cry21A. The 68,000
F2 animals were taken from a larger population of 1,300,000 F2
animals that came from 240,000 mutagenized F1 animals.
Animals were incubated for 72 hours at 20uC and scored for
overall health, including color, size, movement and brood size.
Clonal lines were established from candidates and retested.
Complementation tests, mapping, and sequencing of
ye49; rescue experiments
Complementation tests were performed by testing F1 progeny
from the cross between egl-9(sa307) males and dpy-17(e164);ye49
hermaphrodites. As a control, cross-progeny from egl-9(sa307)
males into dpy-17(e164) and from N2 males into dpy-17(e164);ye49
were also tested. ye49 was mapped between dpy-11(e224) and
unc-76(e911) using standard three-factor mapping. A dpy-11(e224)
ye49 unc-76(e911) triple mutant was then made in order to perform
single nucleotide polymorphism mapping with the Hawaiian strain
(CB4856) [51].
Genomic DNA and cDNA prepared from egl-9(ye49) animals
were used to sequence the egl-9 gene. For transformation rescue, a
13.4kb-PCR fragment covering from 3kb upstream to 2kb
downstream of egl-9 transcript was amplified with primers
GAGCAACTCGTGGGTTTGTT and CTTCCAGAGGCG-
TTGTCTTC using the LongAmp Taq (Biolabs) from N2
genomic DNA and injected in egl-9(ye49) worms as described [52].
Figure 5. Intestinal specific expression of egl-9 is sufficient to
rescue Cry21A PFT resistance. Resistance to Cry21A was compared
among wild type N2, egl-9(sa307), egl-9(sa307) transformed with cpr-
1::gfp, and egl-9(sa307) animals transformed with cpr1::egl-9. Two
representative worms are shown for each strain 48 h after feeding on
E. coli-expressed Cry21A. Wild-type animals and egl-9(sa307) animals
transformed with cpr1::egl-9 are similarly sensitive to Cry21A whereas
egl-9(sa307) animals and egl-9(sa307) animals transformed with cpr-
1::gfp are relatively resistant.
doi:10.1371/journal.ppat.1000689.g005
Figure 6. nhr-57, a HIF-1-target, is required for loss of egl-9-
mediated resistance to PFT. Wild-type N2 and egl-9(sa307) mutant
animals were treated to RNAi using either empty vector (L4440) or
dsRNA for nhr-57 and exposed to E. coli-expressed Cry21A PFT for
48 hours. Shown are representative animals for each condition. All
animals are healthy in the absence of Cry21A. On Cry21A, whereas egl-
9(sa307) animals are resistant (third row), nhr-57(RNAi) egl-9(sa307)
animals are not.
doi:10.1371/journal.ppat.1000689.g006
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structed by PCR amplification of unc-31 and cpr-1 promoters and
then fused to egl-9 and gfp open reading frames using the Multisite
Gateway cloning system (Invitrogen) and pCG150 (containing
unc-119 rescuing fragment) [53]. The constructs were verified by
sequencing and integrated into HY0843 [unc-119(ed3);egl-9(sa307)]
by ballistic bombardment [54] with a PDS-1000/He Biolistic
Particle Delivery System (Bio-Rad, Hercules, CA). Two indepen-
dent lines of each transgenic strain were examined.
Mortality, morbidity, RNAi and hypoxia assays
For Cry21A E. coli toxin assays, we used E. coli JM103 with
pQE9 empty vector or a cry21A gene insert under control of the
lacZ promoter [11]. Since Cry21A is expressed at very high levels
by E. coli [11] and too potent for scoring for resistance, we diluted
the toxin-expressing bacteria with non-toxin-expressing bacteria at
a ratio of 1:40 for all tests in this study, similar to that previously
described for Cry5B studies [13,15].
Dose-dependent mortality assays with purified Cry5B were
performed as described [52]; hermaphrodite viability was scored
after 6 days at 25uC. Cry21A SCLs were used for quantitative
mortality assays as described above except hermaphrodite viability
was scored after 72 hours at 20uC. Each assay was set up with
triplicate wells for each concentration of Cry toxin, and each
experiment was performed in at least three independent trials.
Typically 180 worms were scored for each concentration.
V. cholerae lifespan assay was performed as described [55] except
the overnight culture was spread on Brain Heart Infusion (BHI)
Figure 7. Cry5B PFT activate the hypoxia pathway and hypoxia confers protection against PFTs. (A) Quantitative real-time PCR analysis of
nhr-57 expression in glp-4(bn2) animals upon treatment on Cry5B for 1, 2, 4 and 8 hours relative to expression levels in no-toxin treatment animals. Data
are averaged from three independent experiments. Error bars represent standard error of the mean, * represents P value,0.05 and *** P value,0.001.
(B) Resistance to Cry5B PFT was compared among wild-type N2 worms in normoxia (top two rows) and in hypoxia (2% O2) (rows 3 and 4) and among
hif-1(ia04) mutant animals in normoxia (rows 5 and 6) and in hypoxia (bottom two rows). Wild-type worms co-treated with hypoxia and Cry5B are
significantly healthier (larger, darker color, more embryos, more motile) than worms treated with Cry5B under normoxia. In contrast, hif-1(ia04) mutant
animals on Cry5B PFT look similarly sick either in the normoxic or in the hypoxic environment. Scale bar is 0.2 mm. (C) Schematic illustrating our results
andrelationship betweentheHIF-1pathwayandPFTINCED.InresponsetoPFT,thehypoxiaresponseisactivatedbysuppressionofEGL-9,eitherbylow
oxygen and/or other means. HIF-1 activates expression of target genes that protect against PFT intoxication, such as nhr-57. Activation of HIF-1 is also
able to activate the XBP-1 arm of the UPR defense pathway.
doi:10.1371/journal.ppat.1000689.g007
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hlyA::(ctxB mer) Hg
r strains, derived from V. cholerae El Tor E7946,
were used [56]. The experiment was performed three times with
approximately 50 worms per strain at room temperature (22uC).
P. aeruginosa lifespan assays were performed on slow-killing plates as
described [15]. Heat shock assays were performed as described
[57]. For the oxidative stress analysis, synchronized young adults
were exposed to 7.5 mM t-butyl hydrogen peroxide as described
[58] and were observed after 6 hours. Life-span assays were
initiated by allowing adult hermaphrodites to lay eggs on NG
plates spread with OP50. When these eggs hatched and the
nematodes reached the L4 stage they were transferred to fresh NG
plates with OP50 supplemented with 25 mM 5-fluorodeoxyuridine
(FUDR) to prevent eggs from hatching. The nematodes were
scored for live/dead every 48 hours by tapping the nose at least
three times (no movement for all taps was scored as dead).
For RNAi tests, adult hermaphrodites were allowed to lay eggs
on NG plates containing 100 mM Isopropyl b-D-1-thiogalactopyr-
anoside (IPTG) and 50 mg/mL ampicillin spread with E. coli strain
HT115 expressing double-stranded (ds) RNA (from the Ahringer
library [59]) for 8 hours and then removed. The eggs were allowed
to develop into L4 larvae on RNAi plates at 20uC. L4
hermaphrodites (ten per genotype or line) were picked onto toxin
plates spread with 100 ml of a mixture of E. coli strain HT115
expressing the same dsRNA and HT115 harboring cry21A-
expressing vector at the ratio 40:1. For no toxin control plates,
100 ml of HT115 with dsRNA was spread. nhr-57(RNAi) testing on
Cry5B PFT was performed slightly differently (Kao et al.,
manuscript in preparation). Briefly, rrf-3(pk1426) animals were
fed E. coli-expressing dsRNA in liquid media with 1mM IPTG at
25uC for ,30 h. 20 mg/ml of Cry5B or 20 mM HEPES control
were then added, as well as 200 mM FUdR. Hermaphrodites
viability was scored after 6 days at 25uC. (As this assay is set up
differently, direct comparison with dose-dependent mortality
assays presented in Table 1 and associated Figures is not possible).
To test worms under hypoxia, L4 wild type and hif-1(ia04)
mutant animals were pipetted onto toxin plates spread with 30 ml
of a mixture of E. coli OP50 strains expressing or not Cry5B at the
ratio 1:1. Plates were placed immediately in a 2% O2 chamber for
24 hours, while control plates were placed in room air. Images
were taken with an Olympus BX60 microscope as described [15].
Real time PCR
Real time PCR was performed as described [15]. To determine
the levels of spliced xbp-1 mRNA, we used primers xbp-1_sqf2
GCATGCATCTACCAGAACGTC and xbp-1_sqr2 GTTCC-
CACTGCTGATTCAAAG to amplify cDNA from wild-type and
egl-9(sa307) animals. The forward primer xbp-1_sqf2 anneals to
exon 1 and the reverse primer xbp-1_sqr2 anneals to the exon1-
exon 2 junction sequence produced when intron 1 is spliced out.
The experiment was carried out using two independent sets of
cDNA and two repeats within each set. Primers TTATC-
GAGTTTCTCGCATTGG and AAGTCTGCAATCACGC-
TCTGT were used to quantify expression of nhr-57. Induction
of expression of nhr-57 by Cry5B was tested in glp-4(bn2) animals
treated for 1, 2, 4 and 8 hours on E. coli OP50 strains expressing
Cry5B or not. The experiment was carried out using three
independent sets of cDNA. Normalization in all cases was to eft-2
transcript levels.
Statistical analyses
LC50 values were determined by PROBIT analysis [60].
Mortality assays were plotted using GraphPad Prism 5.0 (San
Diego). Statistical analysis between two values was compared with
a paired t-test. Statistical analysis among three or more values of
one independent variable was done with matched one-way
ANOVA with Tukey’s method and of more than two independent
variables by two-way ANOVA with the Bonferroni post test. For
lifespan analysis, survival fractions were calculated using the
Kaplan-Meier method and survival curves compared using the
logrank test. Statistical significance was set at P,0.05.
Supporting Information
Figure S1 egl-9 mutant animals resist Cry21A PFT-induced
sterility. Numbers given are the relative brood sizes of wild-type
N2 and egl-9(ye49) animals on Cry21A normalized to no-toxin
controls (mean of three independent assays). For brood size assays,
L4 hermaphrodites from N2 and egl-9(ye49) were picked one each
to four to six plates and incubated at 20uC. Every 24 h, the
originally picked worms would be picked to a new plate; progeny
from the old plate were counted 24 h later. This process was
continued until the original parents ceased to produce progeny.
On E. coli plates expressing Cry21A, N2 animals show a 6.2-fold
reduction in fertility, while egl-9(ye49) show only a 1.5-fold
reduction in fertility. Error bar represents standard error of the
mean. P=0.03 (one-tailed T test).
Found at: doi:10.1371/journal.ppat.1000689.s001 (0.87 MB PDF)
Figure S2 rhy-1 mutation confers resistance to Cry21A PFT.
Dose-dependent mortality assays were performed using Cry21A
spore crystal lysates to quantitatively compare sensitivities of wild-
type N2 and rhy-1(ok1402) mutants. Each data point shows the
mean and standard error of the mean from three independent
experiments (three wells per experiment; ,180 animals per data
point). Statistical differences between mutant strains and N2 are
given for each concentration using P values represented by
asterisks as follows: * P,0.05; ** P,0.01; *** P,0.001. LC50
values and % alive at specific doses are reported in Table 1.
Found at: doi:10.1371/journal.ppat.1000689.s002 (1.98 MB PDF)
Figure S3 RNAi confirmation that Cry21A resistance associated
with loss of EGL-9 is mediated through HIF-1. Wild-type N2, egl-
9(sa307), and hif-1(ia04) mutant animals were treated with RNAi
of either empty vector (L4440), egl-9, hif-1 or dpy-3 (positive control
for RNAi effectiveness) and exposed to E. coli expressed Cry21A
PFT for 48 hours. When put on toxin plates, only wild-type
animals on egl-9(RNAi) and egl-9(sa307) on either empty vector,
egl-9(RNAi),o rdpy-3(RNAi) display a resistance phenotype. RNAi
of hif-1 in the presence of egl-9(sa307) suppresses Cry21A PFT
resistance. RNAi of egl-9 in the presence of hif-1(ia04) does not
confer resistance to Cry21A. Scale bar is 0.5 mm.
Found at: doi:10.1371/journal.ppat.1000689.s003 (4.07 MB PDF)
Figure S4 Hypoxia confers protection against Cry5B PFT.
Resistance to Cry5B PFT was compared among wild-type N2
worms in normoxia (top two rows) and in hypoxia (1.5% O2) for
72 hours (bottom two rows). Worms co-treated with hypoxia and
Cry5B are significantly healthier (larger, darker color, more
embryos, more motile) than worms treated with Cry5B under
normoxia. Scale bar is 0.2 mm.
Found at: doi:10.1371/journal.ppat.1000689.s004 (0.55 MB PDF)
Table S1 Data and analyses of VCC, PA14, and lifespan repeat
assays.
Found at: doi:10.1371/journal.ppat.1000689.s005 (0.10 MB PDF)
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